Bisphosphonate-induced necrosis of the jaws: A reconstructive nightmare

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 16, Issue 4, 2008, Pages 325-330

  Gevorgyan, Artur ^a   Enepekides, Danny J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Bisphosphonates; Diphosphonates; Jaw; Mandible; Osteonecrosis

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; IBANDRONIC ACID; METRONIDAZOLE; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ANTIBIOTIC THERAPY; BONE FRAGILITY; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DENTAL CARE; DISEASE COURSE; DRUG ABSORPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEAD AND NECK SURGERY; HUMAN; HYPERBARIC OXYGEN; HYPERCALCEMIA; JAW OSTEONECROSIS; LOW LEVEL LASER THERAPY; MANDIBLE; MANDIBLE RESECTION; MAXILLA; MAXILLA RESECTION; MULTIPLE MYELOMA; MYALGIA; ORAL SURGERY; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW; SURGEON; TOOTH INJURY; TREATMENT INDICATION; BONE TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; MALE; METASTASIS; RISK FACTOR;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAW DISEASES; MALE; OSTEONECROSIS; OSTEOPOROSIS; OSTEORADIONECROSIS; RISK FACTORS;

EID: 52449115727     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e328304b445     Document Type: Review

References (39)

1. Fleisch H, ReszkaA, Rodan G, et al. Bisphosphonates: mechanisms of action. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego, California: Academic Press; 2002. pp. 1361-1385.
2. Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003; 14:1468-1476.
3. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753-761.
4. Bilezikian JP. Osteonecrosis of the jaw: do bisphosphonates pose a risk? N Engl J Med 2006; 355:2278-2281.
5. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349:457-463.
6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
7. KhoslaS, BurrD,CauleyJ, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-1491.
8. Phal PM, Myall RW, Assael LA, et al. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 2007; 28: 1139-1145.
9. Catalano L, Del VecchioS, Petruzziello F, et al. Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. Ann Hematol 2007; 86: 415-423.
10. Bianchi SD, Scoletta M, Cassione FB, et al. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:249-258.
11. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567-1575.
12. Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983; 41:283-288.
13. Reuther T, Schuster T, Mende U, et al. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients: a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 2003;32:289-295.
14. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-534.
15. Zarychanski R, Elphee E, Walton P, et al. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006; 81:73-75.
16. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006; 35:588-593.
17. Wutzl A, Eisenmenger G, Hoffmann M, et al. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 2006; 118:473-478.
18. Merigo E, Manfredi M, Meleti M, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 2006; 77:109-117.
19. Dannemann C, Zwahlen R, Gratz KW. Clinical experiences with bisphosphonate induced osteochemonecrosis of the jaws. Swiss Med Wkly 2006; 136:504-509.
20. AgrilloA, Petrucci MT,Tedaldi M, et al. Newtherapeutic protocol in thetreatment of avascular necrosis of the jaws. J Craniofac Surg 2006; 17:1080-1083.
21. Shimura K, Shimazaki C, Taniguchi K, et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 2006; 84:343-345.
22. Pozzi S, Marcheselli R, Sacchi S, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007; 48:56-64.
23. Eckert AW, Maurer P, Meyer L, et al. Bisphosphonate-related jaw necrosis: severe complication in maxillofacial surgery. Cancer Treat Rev 2007; 33:58-63.
24. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65:415-423.
25. Magopoulos C, Karakinaris G, Telioudis Z, et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol 2007; 28:158-163.
26. Heras Rincon I, Zubillaga Rodriguez I, Castrillo Tambay M, et al. Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations. Med Oral Patol Oral Cir Bucal 2007; 12:E267-E271.
27. LongobardiG, BonielloR, GaspariniG, et al. Surgical therapy for osteonecrotic lesions of the jaws in patients in therapy with bisphosphonates. J Craniofac Surg 2007; 18:1012-1017.
28. Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007; 18:1363-1370.
29. Vieillard MH, Maes JM, Penel G, et al. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 2008; 75:34-40.
30. Nastro E, Musolino C, Allegra A, et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 2007; 117:181 -187.
31. Abu-Id MH, Warnke PH, Gottschalk J, et al. 'Bis-phossy jaws' - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Cranio-maxillofac Surg 2008; 36:95-103.
32. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65:2397-2410.
33. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007; 65:1321 -1327.
34. Montebugnoli L, Felicetti L, Gissi DB, et al. Bisphosphonate- associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:473-477.
35. Vescovi P, Merigo E, Meleti M, et al. Nd:YAG laser biostimulation of bisphosphonate-associated necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg 2007; 45:628-632.
36. Vescovi P, Merigo E, Manfredi M, et al. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surg 2008; 26:37-46.
37. Agrillo A, Ungari C, Filiaci F, et al. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 2007; 18:1071 -1075.
38. American Association of Oral and Maxillofacial Surgeons position. Paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-376.
39. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006; 137:1144-1150.